Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%,
and 10%) and inhaled placebo cannabis for the acute treatment of migraine.